For research use only. Not for therapeutic Use.
MK2-IN-5 (Hsp25 kinase inhibitor) acetate is a Mk2 pseudosubstrate (Ki= 8 μM). MK2-IN-5 acetate targets the protein interaction domain in the MAPK pathway. MK2-IN-5 acetate inhibits HSP25 and HSP27 phosphorylation[1][2][3].
MK2-IN-5 acetate (5-10 μM, 2 h) inhibits TGF-b1 induced connective tissue growth factor (CTGF) and collagen type I in primary human keloid fibroblasts[3].
MK2-IN-5 acetate (2 mg/kg Intraperitoneal injection, single dose) decreased HSP25 phosphorylation in ventilator-associated lung injury model[2].
Catalog Number | I040101 |
Molecular Formula | C61H113N21O16.xC2H4O2 |
Purity | ≥95% |
Reference | [1]. Gaestel M, et al. Peptides as signaling inhibitors for mammalian MAP kinase cascades [J]. Current pharmaceutical design, 2009, 15(21): 2471-2480. [2]. Damarla M, et al. Mitogen activated protein kinase activated protein kinase 2 regulates actin polymerization and vascular leak in ventilator associated lung injury [J]. PloS one, 2009, 4(2): e4600. [3]. Lopes L B, et al. Inhibition of HSP27 phosphorylation by a cell-permeant MAPKAP Kinase 2 inhibitor [J]. Biochemical and biophysical research communications, 2009, 382(3): 535-539. |